Presentation Dates and Times:

-- Tuesday, November 4, 2008 -- Hourly from 2:00 p.m. to 5:45 p.m. PT

-- Wednesday, November 5, 2008 -- Hourly from 8:00 a.m. to 12:45 p.m. PT

Over 800 investors are expected to participate in the AeA Classic Conference hosted by AeA, the nation's largest high-tech trade association.

ABOUT ACACIA RESEARCH CORPORATION

Acacia Research's subsidiaries develop, acquire, and license patented technologies. Acacia Research's subsidiaries control 99 patent portfolios, which include U.S. patents and certain foreign counterparts, covering technologies used in a wide variety of industries.

Information about Acacia Research is available at www.acaciatechnologies.com and www.acaciaresearch.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

SOURCE: Acacia Research Corporation

Acacia Research Corporation 
Rob Stewart, Investor Relations, 949-480-8300 
Fax: 949-480-8301

The call will also be simultaneously broadcast over the Internet. To listen to the live webcast, please go to www.medistechnologies.com and click on the conference call link. The conference call will be archived and accessible for approximately 30 days if you are unable to listen to the live call.

Schedule this webcast into MS-Outlook calendar (click open when prompted): http://apps.shareholder.com/PNWOutlook/t.aspx?m=33943&k=3C2AD325

Medis Technologies' primary focus is on its fuel cell technology. Its business strategy is to sell its products to end users through retail outlets, service providers and to the military and other markets. Medis' majority-owned and publicly traded subsidiary, Cell Kinetics Ltd., is engaged in the development and commercialization of the CKChip, a unique cell carrier platform intended for simultaneous fluoroscopic monitoring and analysis of thousands of individual living cells over time.

This press release may contain forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify those so-called "forward looking statements" by words such as "may," "will," "should," "expects," "plans," "targets," "believes," "anticipates," "estimates," "predicts," "potential," or "continue" or the negative of those words and other comparable words. These forward-looking statements are subject to risks and uncertainties, product tests, commercialization risks, availability of financing and results of financing efforts that could cause actual results to differ materially from historical results or those anticipated. Further information regarding these and other risks is described from time to time in the Company's filings with the SEC. We assume no obligation to update or alter our forward-looking statements made in this release or in any periodic report filed by us under the Securities Exchange Act of 1934 or any other document, whether as a result of new information, future events or otherwise, except as otherwise required by applicable federal securities laws.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Shareholder.com; Medis Technologies Ltd.

Medis Technologies Ltd.
          Jose Mejia, Chief Executive Officer
          (212) 935-8484

          The Equity Group Inc.
          Adam Prior, Vice President
          212 836-9606
          aprior@equityny.com

"Sustaining high revenue growth over five years is an exceptional accomplishment," said Michael J. Purcell, Greater Philadelphia Marketplace Technology, Media and Telecommunications Leader, Deloitte & Touche LLP. "We commend PhotoMedex for making the commitment to technology and delivering on the promise of market longevity. We are proud to name PhotoMedex to Deloitte's Fast 50."

The Greater Philadelphia Technology Fast 50 program is presented by Deloitte and sponsored by Fragomen, Del Rey, Bernsen & Loewy LLP, The Judge Group and UK Trade and Investment.

To qualify for the Technology Fast 50, companies must have had operating revenues of at least $50,000 in 2003 and $5 million in 2007, be headquartered in North America, and be a company that owns proprietary technology or proprietary intellectual property that contributes to a significant portion of the company's operating revenues; or devotes a significant proportion of revenues to the research and development of technology. Using other companies' technology or intellectual property in a unique way does not qualify.

Winners of the regional Fast 50 programs in the United States and Canada are automatically entered in Deloitte's Technology Fast 500 program, which ranks the top 500 fastest growing technology, media, telecommunications and life sciences companies. For more information on Deloitte's Fast 50 or Fast 500 programs, visit www.fast500.com.

About PhotoMedex

PhotoMedex offers a wide range of products and services across multiple specialty areas, including dermatology, urology, gynecology, orthopedics and other surgical specialties. PhotoMedex is a leader in the development, manufacturing and marketing of medical laser products and services. PhotoMedex also develops and markets products based on its patented, clinically proven Copper Peptide technology for skin health, hair care and wound care. PhotoMedex sells directly to dermatologists, plastic and cosmetic surgeons, spas and salons and through licenses with strategic partners into the consumer market, including a long-term worldwide license agreement with Neutrogena(R), a Johnson & Johnson company. ProCyte brands include Neova(R), Ti-Silc(R), VitalCopper(R), Simple Solutions(R) and AquaSante(R).

Safe Harbor Statement

Some portions of the conference call, particularly those describing PhotoMedex' strategies, operating expense reductions and business plans and the other proposed transactions described in this press release, will contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While PhotoMedex is working to achieve those goals, actual results could differ materially from those projected in the forward-looking statements as a result of a number of factors, including continued increase in XTRAC procedures performed, difficulties in marketing its products and services, need for capital, competition from other companies, risks relating to technology and product development, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on strategic partners, the closing of the proposed Photo Therapeutics acquisition, and the related financing from Perseus, L.L.C. (the "Proposed Financing") and the benefits and risks of this proposed acquisition and related financing, and other factors, any of which could have an adverse effect on the business plans of PhotoMedex, its reputation in the industry or its results. In light of significant uncertainties inherent in forward-looking statements included herein and in the conference call, the inclusion of such information in the conference call should not be regarded as a representation by PhotoMedex or its subsidiaries that the forward-looking statements will be achieved. For further details and a discussion of these and other risks and uncertainties, please see our annual report on 2007 Annual Report on Form 10-K, filed with the SEC on March 17, 2008, as amended by the Company's annual report on Form 10-K/A, and our other period reports which are on file with the SEC. We undertake no obligation to publicly update any forward-looking statement, either as a result of new information, future events or otherwise.

SOURCE: PhotoMedex, Inc.

Lippert/Heilshorn & Associates, Inc. 
Kim Sutton Golodetz (investors), 212-838-3777 
Kgolodetz@lhai.com 
or 
Bruce Voss, 310-691-7100 
Bvoss@lhai.com 
or 
PhotoMedex, Inc. 
Dennis McGrath, CFO, 215-619-3287 
info@photomedex.com

Expected next investor conference call information:
Conference Call Date: 10/23/2008
Conference Call Time: 4:30 PM
Conference Call URL: http://www.acaciaresearch.com/investors_main.htm